Patent 12403095
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Veloxis Pharmaceuticals AS
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There are no AIA trial proceedings on file for U.S. Patent 12,403,095. This indicates that the patent has not yet been challenged in an IPR, PGR, or CBM proceeding at the USPTO's Patent Trial and Appeal Board.
Strategic summary
As of May 30, 2026, all claims of U.S. Patent 12,403,095 (claims 1-21) remain untested by the PTAB. There is no estoppel landscape to consider as no AIA trials have been initiated. The absence of PTAB activity might suggest that the patent has not yet been heavily asserted in a manner that would provoke an IPR filing, or potential challengers have not yet identified strong grounds for invalidation under the AIA trial standards.
Recommended next steps
Since no PTAB activity exists for U.S. Patent 12,403,095, any defendant currently facing assertion of this patent has a full range of prior-art grounds available for potential IPR or PGR challenges. If considering such a challenge, it would be prudent to conduct a thorough prior art search, focusing on the novelty and obviousness of claims 1 and 11 (the independent claims), as well as their dependent claims. The absence of PTAB challenges to date could be a signal, but it does not preclude the possibility of successful challenges in the future.
Generated 5/30/2026, 6:48:49 AM